Lorena Lerner, Newton Centre, MA (US); Sandra Abbott, Boston, MA (US); Ailin Bai, Newton, MA (US); Ting Chen, Acton, MA (US); Maria Isabel Chiu, Newton Centre, MA (US); Qing Liu, Acton, MA (US); Laura Poling, Boston, MA (US); Nianjun Tao, Brighton, MA (US); Solly Weiler, Newton, MA (US); Zhigang Weng, Brookline, MA (US); William M. Winston, Jr., Marlborough, MA (US); and Jeno Gyuris, Lincoln, MA (US)
Assigned to AVEO Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by AVEO Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Jun. 16, 2023, as Appl. No. 18/336,713.
Application 14/863,870 is a division of application No. 14/137,415, filed on Dec. 20, 2013, granted, now 9,175,076, issued on Nov. 3, 2015.
Application 18/336,713 is a continuation of application No. 16/824,034, filed on Mar. 19, 2020, granted, now 11,725,047.
Application 16/824,034 is a continuation of application No. 15/655,263, filed on Jul. 20, 2017, granted, now 10,597,444, issued on Mar. 24, 2020.
Application 15/655,263 is a continuation of application No. 14/863,870, filed on Sep. 24, 2015, granted, now 9,725,505, issued on Aug. 8, 2017.
Claims priority of provisional application 61/827,325, filed on May 24, 2013.
Claims priority of provisional application 61/745,508, filed on Dec. 21, 2012.
Prior Publication US 2024/0166734 A1, May 23, 2024
1. A method of treating cachexia in a mammal comprising administering to the mammal an effective amount of an anti-GDF15 antibody or antigen-binding fragment thereof comprising a CDR H1, a CDR H2, a CDR H3, a CDR L1, a CDR L2, and a CDR L3, wherein the CDR H1, CDR H2, and CDR H3 are found in the amino acid sequence of SEQ ID NO: 250, and wherein the CDR L1, CDR L2, and CDR L3 are found in the amino acid sequence of SEQ ID NO: 92.